Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool June 26, 2009 Brian Orelli	Change at Top Looks Good for Bottom Line Investors welcome Boston Scientific's new boss.
The Motley Fool February 12, 2010 Brian Orelli	Too Bad It's Not in the "Restructuring" Business Shares of Boston Scientific slipped nearly 10% yesterday, after the company released earnings and guidance for this year.
The Motley Fool February 3, 2011 Brian Orelli	Add This Stock to Your Show-Me List Wait for the turnaround before investing in Boston Scientific; if it ever comes.
The Motley Fool June 29, 2006 Jim Mueller	Guidant, Devices, and Recalls, Oh My! To repair its acquisition's good name, Boston Scientific must quickly fix Guidant's problems. One analyst sees annual growth for Guidant's devices in the 10% to 15% range. No one knows how accurate that will prove to be, but it certainly provides hope for the troubled acquisition.
The Motley Fool December 13, 2011 Dan Caplinger	Has Boston Scientific Become the Perfect Stock? Since we looked at Boston Scientific last year, the maker of medical devices has gotten up off the mat and quadrupled its score.
The Motley Fool April 9, 2010 Brian Orelli	Is Boston Scientific Turning It Around? Selling off a pair of units could help.
The Motley Fool February 3, 2011 Thomas Lee	Boston Scientific Wants to Be a Rock Star. But First, It Needs Some Stars Boston Scientific has been talking the talk of late. But its walk the past few years can be best described as a limp.
The Motley Fool February 7, 2006 Stephen D. Simpson	Boston Scientific's Big Task The company won the battle for Guidant, but the hard work hasn't even begun. Value is value, and if Boston Scientific proves it can handle the considerable challenges ahead, this could ultimately be a very interesting stock again.
The Motley Fool September 29, 2010 Brian Orelli	Boston Scientific: Strengths, Weaknesses, Opportunities, Threats One of the best ways to develop a picture of any company is with the SWOT analysis -- a look at a company's strengths, weaknesses, opportunities, and threats. Let's take a look at Boston Scientific in this light as it tries to turn itself around.
The Motley Fool July 23, 2008 Brian Orelli	Leaner Boston Scientific Isn't Looking Healthy Investors are rightfully growing weary of Boston Scientific's ability to cut expenses on flat sales, and they send the stock down.
The Motley Fool January 29, 2009 Brian Orelli	No Buyer's Remorse at Boston Scientific The pacemakers and defibrillators that Guidant contributed to Boston Scientific's bottom line are still growing strong, but the company had to take a whopping $2.7 billion goodwill writedown because the value of what it purchased has changed.
The Motley Fool October 23, 2008 Brian Orelli	Boston Scientific Should Be Thankful The medical device maker's two-year-old acquisition of Guidant has saved it in the third quarter.
The Motley Fool August 12, 2010 Brian Orelli	Turnaround Signal, or Just Noise on the Decline? Boston Scientific clears up an FDA warning letter -- four years later.
The Motley Fool July 31, 2006 Stephen D. Simpson	Can Boston Scientific Get It Right? To boost investor confidence, management must first prove itself.
The Motley Fool July 21, 2010 Brian Orelli	Boston Scientific Bounces When you're as beaten-down as Boston Scientific, you seemingly have nowhere to go but up. There's also bankruptcy, but the beleaguered medical device maker seems far from that -- at least for now.
The Motley Fool May 29, 2008 Brian Orelli	Medtronic Sticks It to Boston Scientific Medtronic wins the medical-device patent duel with Boston Scientific.
The Motley Fool April 23, 2008 Brian Orelli	Boston Scientific Gets It Done After a rough 2007, it looks like Boston Scientific is turning itself around from the bottom up.
The Motley Fool June 13, 2006 Jim Mueller	Foolish Investing and Boston Scientific In having bought Guidant, Boston Scientific might end up paying more than just the price. Investors, take note.
The Motley Fool September 14, 2011 Brian Orelli	How to Muck Up a Turnaround in 12 and a Half Months Boston Scientific's choice for a new CEO has the potential to really muck up its recovery even further -- if that's even possible.
The Motley Fool May 28, 2004 W.D. Crotty	Boston Scientific's Stent Gold Mine The company is starting two or more years of high profitability.
The Motley Fool October 13, 2008 Brian Orelli	Too Little Too Late for Boston Scientific The company gets new stent approved, but it should have happened earlier.
The Motley Fool July 29, 2011 Brian Orelli	Boston Scientific Shows Me The company has shown it can hit its mark for at least one quarter, but can it last?
The Motley Fool August 6, 2004 Jeff Hwang	Stent Recall Stings Medical device maker Boston Scientific's recall has happened at a crucial time. Will the company lose its market share?
The Motley Fool February 1, 2010 Brian Orelli	Now That's Some Expensive Risk Mitigation Boston Scientific avoids a trial -- but at a dear cost.
The Motley Fool April 19, 2005 Stephen D. Simpson	Stent Success Propels Boston Scientific The medical device company's still ahead of the competition. Companies dependent upon one product line may be riskier than average, but there's no question that they can reap big-time profits when business is good.
The Motley Fool December 31, 2007 Brian Orelli	Boston Scientific Restarts Its Heart Boston Scientific receives European approval for its defibrillator, giving the company a revenue boost even if the U.S. approval is delayed.
The Motley Fool May 25, 2010 Brian Orelli	Medtronic Gets Tossed Out With the Bathwater A bad day to report good news.
The Motley Fool September 21, 2010 Brian Orelli	An Acquisition Helps Boston Scientific Breathe Easier Boston Scientific diversifies by picking up device maker Asthmatx.
The Motley Fool December 5, 2005 Stephen D. Simpson	Boston Scientific's Bold Move Acquiring Guidant would be risky, but it would give Boston Scientific exactly what it needs. It will be curious to see how J&J responds to this deal. Investors, take note.
The Motley Fool June 1, 2004 Jeff Hwang	Expanding Boston Scientific The medical device maker takes advantage of Taxus sales to expand.
The Motley Fool February 1, 2005 Stephen D. Simpson	Stent Maker's Hearty Returns Medical device company Boston Scientific rebounds from cardiac stent recall with strong growth.
The Motley Fool February 5, 2008 Brian Orelli	Boston Scientific Gets Charged Walloped by charges, Boston Scientific posts a loss for the quarter.
The Motley Fool September 26, 2005 Stephen D. Simpson	Boston Scientific: Finally Cheap Enough? Could shares of the medical device company now be attractive for long-term investors?
The Motley Fool September 11, 2007 Billy Fisher	FDA Takes Issue With Boston Scientific Boston Scientific has until later this month to respond to an FDA letter prompted by the company's failure to disclose two of five deaths in a stent trial that the medical device maker abandoned in 2006. Investors take note.
The Motley Fool November 11, 2009 Jim Mueller	This Company Is a Value Stock! Isn't It? A look at Boston Scientific leads to conflicting conclusions.
The Motley Fool March 16, 2010 Brian Orelli	No Matter What You Call It, It Still Stinks A recall over a paperwork issue? What have you guys been doing? Announcing a recall of your heart defibrillators during a major cardiology meeting probably isn't the best move
The Motley Fool July 23, 2007 Ryan Fuhrmann	Boston Scientific Still Drowsy Facing continued top-line weakness, the medical device company may have to cut costs. Investors, take note.
The Motley Fool June 24, 2009 Brian Orelli	Boston Scientific Helps Itself ... and Its Rivals Boston Scientific released positive results from a clinical trial testing its heart devices, but unfortunately the data is likely to help its competitors as well.
The Motley Fool April 27, 2010 Brian Orelli	Boston Scientific's "Challenging" Quarter Boston Scientific fixed its paperwork problem with the Food and Drug Administration earlier this month, but the resulting recall took its toll on first-quarter profits nonetheless.
The Motley Fool February 15, 2006 Tim Beyers	Who's Buying Now? Sometimes, insiders are buying for all the right reasons. Who's buying now? Boston Scientific... Franklin Bank... Fossil... Gartner... iPass...
The Motley Fool August 24, 2010 Brian Orelli	Disaster in Medical-Device Land Industry bellwether Medtronic is forecasting a nasty storm.
The Motley Fool July 7, 2008 Brian Orelli	And Then There Were 4 The number of drug-eluting stent players in the U.S. doubles with the addition of Medtronic's Endeavor and Abbott Labs' Xience V.
The Motley Fool May 24, 2006 S.J. Caplan	Goodbye, Guidant Publicity woes drive Boston Scientific to ditch the Guidant name. In the meantime, Boston Scientific wants to capitalize on its entry into the ICD market, an area experiencing double-digit sales growth. Investors, take note.
The Motley Fool July 19, 2005 Stephen D. Simpson	Waiting for Boston Scientific's Second Act The market for drug-coated stents is still lucrative, but BSX needs to deliver on its R&D efforts for long-term success. Investors, take note.
The Motley Fool October 20, 2006 Ryan Fuhrmann	Boston's Unscientific Results Boston Scientific reported third-quarter results that were at the upper end of the company's late-September earnings warning. The shares have had a rough run lately, down nearly 40% over the past year. Buying opportunity?
The Motley Fool May 25, 2005 Stephen D. Simpson	Stent Wars 2: The Market-Share Menace The battle for drug-coated stent market share between Johnson & Johnson and Boston Scientific may not be as exciting as watching Obi-Wan Kenobi and Anakin Skywalker fight, but the outcome matters for investors.
The Motley Fool October 18, 2010 Anand Chokkavelu	There Are Better Opportunities Than Boston Scientific Let's take a look. By the numbers, Abbott, Medtronic, and Johnson & Johnson all look more compelling than Boston Scientific.
The Motley Fool February 24, 2004 Alyce Lomax	J&J, Guidant Join Forces With intense rivalry looming, is a competitive partnership in vain?
The Motley Fool October 14, 2005 Stephen D. Simpson	Boston's Stunts With Stents Tough domestic stent competition is weighing on results from one-trick pony Boston Scientific. The company is in a transitional period and that's at least part of why the stock is down where it is.
The Motley Fool January 17, 2006 Stephen D. Simpson	High-Stakes Medical Device Chicken Boston Scientific has upped the ante again. Are they bluffing? Their latest offer is $80 a share -- $42 in cash and $38 in stock. Let's hope the board knows what it is doing, because it is staking the company on this.